Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Destiny Pharma announced that the Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to XF-73 (exeporfinium chloride) for the prevention of post-surgical infections caused by Staphylococcus aureus, including Methicillin-Resistant Staphylococcus aureus (MRSA).
Data from four Phase 1/2a studies has shown that XF-73 is rapidly bactericidal, reducing the number of bacteria in the nose quickly. A clinical trial for XF-73, sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is ongoing and expected to be completed shortly.
RELATED: MSSA Infections More Common Than MRSA
XF-73 (exeporfinium chloride) is a novel, synthetic drug with anti-bacterial activity against a broad range of bacteria.
For more information visit Destinypharma.com.
